Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Elsa Bernard^{1

2}, Yasuhito Nannya³, Robert P Hasserjian⁴, Sean M Devlin⁵, Heinz Tuechler⁶, Juan S Medina-Martinez^{1

2}, Tetsuichi Yoshizato³, Yusuke Shiozawa³, Ryunosuke Saiki³, Luca Malcovati^{7

8}, Max F Levine^{1

2}, Juan E Arango^{1

2}, Yangyu Zhou^{1

2}, Francesc Solé⁹, Catherine A Cargo¹⁰, Detlef Haase¹¹, Maria Creignou¹², Ulrich Germing¹³, Yanming Zhang¹⁴, Gunes Gundem¹, Araxe Sarian², Arjan A van de Loosdrecht¹⁵, Martin Jädersten¹², Magnus Tobiasson¹², Olivier Kosmider¹⁶, Matilde Y Follo¹⁷, Felicitas Thol¹⁸, Ronald F Pinheiro¹⁹, Valeria Santini²⁰, Ioannis Kotsianidis²¹, Jacqueline Boultwood²², Fabio P S Santos²³, Julie Schanz¹¹, Senji Kasahara²⁴, Takayuki Ishikawa²⁵, Hisashi Tsurumi²⁶, Akifumi Takaori-Kondo²⁷, Toru Kiguchi²⁸, Chantana Polprasert²⁹, John M Bennett³⁰, Virginia M Klimek³¹, Michael R Savona³², Monika Belickova³³, Christina Ganster¹¹, Laura Palomo⁹, Guillermo Sanz^{34

35}, Lionel Ades³⁶, Matteo Giovanni Della Porta^{37

38}, Harold K Elias³¹, Alexandra G Smith³⁹, Yesenia Werner¹, Minal Patel², Agnès Viale⁴⁰, Katelynd Vanness⁴⁰, Donna S Neuberg⁴¹, Kristen E Stevenson⁴¹, Kamal Menghrajani³¹, Kelly L Bolton³¹, Pierre Fenaux³⁶, Andrea Pellagatti²², Uwe Platzbecker⁴², Michael Heuser¹⁸, Peter Valent⁴³, Shigeru Chiba⁴⁴, Yasushi Miyazaki⁴⁵, Carlo Finelli⁴⁶, Maria Teresa Voso⁴⁷, Lee-Yung Shih⁴⁸, Michaela Fontenay¹⁶, Joop H Jansen⁴⁹, José Cervera⁵⁰, Yoshiko Atsuta⁵¹, Norbert Gattermann¹³, Benjamin L Ebert⁵², Rafael Bejar⁵³, Peter L Greenberg⁵⁴, Mario Cazzola^{7

8}, Eva Hellström-Lindberg¹², Seishi Ogawa³, Elli Papaemmanuil^{55

56}

Affiliations

¹ Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
⁴ Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
⁵ Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁶ , Vienna, Austria.
⁷ Department of Molecular Medicine, University of Pavia, Pavia, Italy.
⁸ Department of Hematology, IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy.
⁹ MDS Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Barcelona, Spain.
¹⁰ Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK.
¹¹ Clinics of Hematology and Medical Oncology, University Medical Center, Göttingen, Germany.
¹² Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
¹³ Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.
¹⁴ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁵ Department of Hematology, VU University Medical Center Amsterdam, Amsterdam, the Netherlands.
¹⁶ Department of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin and Université de Paris, Université Paris Descartes, Paris, France.
¹⁷ Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
¹⁸ Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School, Hannover, Germany.
¹⁹ Drug Research and Development Center, Federal University of Ceara, Ceara, Brazil.
²⁰ MDS Unit, Hematology, AOU Careggi, University of Florence, Florence, Italy.
²¹ Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.
²² Radcliffe Department of Medicine, University of Oxford and Oxford BRC Haematology Theme, Oxford, UK.
²³ Oncology-Hematology Center, Hospital Israelita Albert Einstein, São Paulo, Brazil.
²⁴ Department of Hematology, Gifu Municipal Hospital, Gifu, Japan.
²⁵ Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
²⁶ Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.
²⁷ Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
²⁸ Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan.
²⁹ Department of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
³⁰ Lab. Medicine and Pathology, Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, USA.
³¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³² Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
³³ Department of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
³⁴ Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
³⁵ CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
³⁶ Department of Hematology, Hôpital St Louis and Paris University, Paris, France.
³⁷ Humanitas Clinical and Research Center-IRCCS, Humanitas Cancer Center, Milan, Italy.
³⁸ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
³⁹ Department of Health Sciences, University of York, York, UK.
⁴⁰ Integrated Genomics Operation, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴¹ Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴² Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University of Leipzig, Leipzig, Germany.
⁴³ Department of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
⁴⁴ Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
⁴⁵ Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
⁴⁶ Institute of Hematology, S. Orsola-Malpighi University Hospital, Bologna, Italy.
⁴⁷ MDS Cooperative Group GROM-L, Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
⁴⁸ Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan City, Taiwan.
⁴⁹ Laboratory Hematology, Department LABGK, Radboud University Medical Centre, Nijmegen, the Netherlands.
⁵⁰ Department of Hematology and Genetics Unit, University Hospital La Fe, Valencia, Spain.
⁵¹ Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
⁵² Department of Medical Oncology and Howard Hughes Medical Institute, Dana-Farber Cancer Center, Boston, MA, USA.
⁵³ UC San Diego Moores Cancer Center, La Jolla, CA, USA.
⁵⁴ Stanford University Cancer Institute, Stanford, CA, USA.
⁵⁵ Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. papaemme@mskcc.org.
⁵⁶ Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. papaemme@mskcc.org.

PMID: 33948021
DOI: 10.1038/s41591-021-01367-w

Published Erratum

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Elsa Bernard et al. Nat Med. 2021 May.

. 2021 May;27(5):927.

doi: 10.1038/s41591-021-01367-w.

Authors

Affiliations

¹ Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
⁴ Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
⁵ Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁶ , Vienna, Austria.
⁷ Department of Molecular Medicine, University of Pavia, Pavia, Italy.
⁸ Department of Hematology, IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy.
⁹ MDS Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Barcelona, Spain.
¹⁰ Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK.
¹¹ Clinics of Hematology and Medical Oncology, University Medical Center, Göttingen, Germany.
¹² Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
¹³ Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.
¹⁴ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁵ Department of Hematology, VU University Medical Center Amsterdam, Amsterdam, the Netherlands.
¹⁶ Department of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin and Université de Paris, Université Paris Descartes, Paris, France.
¹⁷ Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
¹⁸ Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School, Hannover, Germany.
¹⁹ Drug Research and Development Center, Federal University of Ceara, Ceara, Brazil.
²⁰ MDS Unit, Hematology, AOU Careggi, University of Florence, Florence, Italy.
²¹ Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.
²² Radcliffe Department of Medicine, University of Oxford and Oxford BRC Haematology Theme, Oxford, UK.
²³ Oncology-Hematology Center, Hospital Israelita Albert Einstein, São Paulo, Brazil.
²⁴ Department of Hematology, Gifu Municipal Hospital, Gifu, Japan.
²⁵ Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
²⁶ Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.
²⁷ Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
²⁸ Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan.
²⁹ Department of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
³⁰ Lab. Medicine and Pathology, Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, USA.
³¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³² Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
³³ Department of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
³⁴ Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
³⁵ CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
³⁶ Department of Hematology, Hôpital St Louis and Paris University, Paris, France.
³⁷ Humanitas Clinical and Research Center-IRCCS, Humanitas Cancer Center, Milan, Italy.
³⁸ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
³⁹ Department of Health Sciences, University of York, York, UK.
⁴⁰ Integrated Genomics Operation, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴¹ Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴² Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University of Leipzig, Leipzig, Germany.
⁴³ Department of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
⁴⁴ Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
⁴⁵ Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
⁴⁶ Institute of Hematology, S. Orsola-Malpighi University Hospital, Bologna, Italy.
⁴⁷ MDS Cooperative Group GROM-L, Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
⁴⁸ Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan City, Taiwan.
⁴⁹ Laboratory Hematology, Department LABGK, Radboud University Medical Centre, Nijmegen, the Netherlands.
⁵⁰ Department of Hematology and Genetics Unit, University Hospital La Fe, Valencia, Spain.
⁵¹ Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
⁵² Department of Medical Oncology and Howard Hughes Medical Institute, Dana-Farber Cancer Center, Boston, MA, USA.
⁵³ UC San Diego Moores Cancer Center, La Jolla, CA, USA.
⁵⁴ Stanford University Cancer Institute, Stanford, CA, USA.
⁵⁵ Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. papaemme@mskcc.org.
⁵⁶ Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. papaemme@mskcc.org.

PMID: 33948021
DOI: 10.1038/s41591-021-01367-w

No abstract available

PubMed Disclaimer

Erratum for

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Elias HK, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E. Bernard E, et al. Nat Med. 2020 Oct;26(10):1549-1556. doi: 10.1038/s41591-020-1008-z. Epub 2020 Aug 3. Nat Med. 2020. PMID: 32747829 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Affiliations

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials

Miscellaneous